Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytokinetics has started second double-blind, randomized, placebo-controlled Phase IIa clinical trial evaluating CK-1827452, a novel cardiac myosin activator being developed by the company for the potential treatment of patients with either acutely decompensated or chronic heart failure.
Subscribe to our email newsletter
This trial is designed to evaluate both intravenous and oral formulations of CK-1827452 in patients with ischemic cardiomyopathy and angina. The primary objective of this trial is to assess the effect of intravenous CK-1827452 on symptom-limited treadmill exercise tolerance. The secondary objectives of this trial are to assess the tolerability and resulting plasma concentrations of CK-1827452 administered as an oral formulation.
CK-1827452 is the subject of a collaboration and option agreement between Cytokinetics and Amgen.
Andrew Wolff, senior vice president of clinical R&D and chief medical officer of Cytokinetics, said: “This trial is another step towards a fuller understanding and characterization of the safety and tolerability of CK-1827452 in patients with heart failure, in this case specifically patients with ischemic cardiomyopathy and angina.”